Want to see JP:4880 full AI Analyst Report?
4880 Stock Chart & Stats
¥399.00
¥37.00(4.48%)
At close: 4:00 PM EST
¥399.00
¥37.00(4.48%)
Day’s Range― - ―
52-Week Range¥294.00 - ¥635.00
Previous CloseN/A
Volume210.70K
Average Volume (3M)37.94K
Market Cap
¥6.87B
Enterprise Value¥2.54K
Total Cash (Recent Filing)¥4.79B
Total Debt (Recent Filing)¥25.26M
Price to Earnings (P/E)97.2
Beta0.91
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.45%
Share Statistics
EPS (TTM)3.56
Shares Outstanding19,851,380
10 Day Avg. Volume39,420
30 Day Avg. Volume37,936
Financial Highlights & Ratios
PEG Ratio-9.79
Price to Book (P/B)1.66
Price to Sales (P/S)2.70
P/FCF Ratio34.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3
Revenue Forecast (FY)¥3.60B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMinimal debt relative to equity and stable assets and equity reduce financing risk, preserving flexibility to fund cell-therapy development, operations and regulatory investment through biotechnology cycles without balance-sheet stress.
Positive Cash GenerationPersistently positive operating and free cash flow provides internally generated liquidity. That is valuable for a biotechnology company because it can support operations and development while reducing dependence on external capital.
Cell-Therapy Service PositionCellSource serves several stages of the regenerative-medicine workflow, including collection, processing, storage and related support. This defined service position gives it multiple avenues to benefit as clinical and research use of cell therapies develops.
Bears Say
Inconsistent Revenue GrowthUneven revenue performance makes the growth outlook less predictable and suggests demand or project timing remains variable. Greater consistency will be needed to support reliable operating leverage and sustained investment in the business.
Profitability DeteriorationThe sharp decline in net and operating profitability indicates that the recent revenue rebound has not translated efficiently into earnings. Persistently weaker margins could limit reinvestment capacity and reduce returns on the company’s otherwise strong balance sheet.
Volatile Cash ConversionPositive cash generation is offset by volatility and weaker recent conversion. In 2025, operating cash flow did not fully cover reported earnings, signaling that reported profitability may not yet translate consistently into liquidity for long-term development.
CellSource Co., Ltd. News
4880 FAQ
What was CellSource Co., Ltd.’s price range in the past 12 months?
CellSource Co., Ltd. lowest stock price was ¥294.00 and its highest was ¥635.00 in the past 12 months.
What is CellSource Co., Ltd.’s market cap?
CellSource Co., Ltd.’s market cap is ¥6.87B.
When is CellSource Co., Ltd.’s upcoming earnings report date?
CellSource Co., Ltd.’s upcoming earnings report date is Sep 08, 2026 which is tomorrow.
How were CellSource Co., Ltd.’s earnings last quarter?
CellSource Co., Ltd. released its earnings results on Jun 10, 2026. The company reported ¥1.89 earnings per share for the quarter.
Is CellSource Co., Ltd. overvalued?
According to Wall Street analysts CellSource Co., Ltd.’s price is currently Overvalued.
Does CellSource Co., Ltd. pay dividends?
CellSource Co., Ltd. pays a Annually dividend of ¥5 which represents an annual dividend yield of 1.45%. See more information on CellSource Co., Ltd. dividends here
What is CellSource Co., Ltd.’s EPS estimate?
CellSource Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CellSource Co., Ltd. have?
CellSource Co., Ltd. has 19,851,380 shares outstanding.
What happened to CellSource Co., Ltd.’s price movement after its last earnings report?
CellSource Co., Ltd. reported an EPS of ¥1.89 in its last earnings report. Following the earnings report the stock price went down -0.631%.
Which hedge fund is a major shareholder of CellSource Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellSource Co., Ltd.
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
Technical Analysis
Healios KK
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―